Status:
COMPLETED
Dexmedetomidine vs. Remifentanil for Sedation During AFI
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
Hospira, now a wholly owned subsidiary of Pfizer
Conditions:
Intubation, Endotracheal
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The objective of this study is to determine the efficacy and safety of Dexmedetomidine, a selective alpha-2 adrenoceptor agonist, which has recently gained increased popularity for ICU and intraoperat...
Detailed Description
Awake nasal or oral fiberoptic intubation remains the method of choice for airway management in the expected difficult airway. This technique requires that a patient be comfortable, relaxed, cooperati...
Eligibility Criteria
Inclusion
- A signed informed consent must be obtained after the nature of the study has been fully explained.
- Patients undergoing any procedure requiring general anesthesia with an endotracheal tube.
- Patients that have been assessed by an attending anesthesiologist to have an airway requiring awake fiberoptic intubation.
- Adult patients \> 18 yrs. old, ASA I - III.
Exclusion
- Patients expected to have severe adverse side effects to Dexmedetomidine including:
- Previous allergy to the drug.
- 3rd degree AV Block
- Hypovolemic hypotension
- Systemic vasoconstriction
- Patients expected to have a severe adverse side effect to Remifentanil. This includes:
- Previous allergy to the drug.
- Patients suspected of being overly sensitive to narcotics.
- Patients with significant cardiovascular disease or ASA physical status IV and V
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00349245
Start Date
June 1 2006
End Date
August 1 2007
Last Update
March 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Hermann Hospital
Houston, Texas, United States, 77030